<!– Name:DistributionId Value:8842266 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9693798e-1145-4284-a4b2-94e05f5c17f2 –>

New York, USA, May 18, 2023 (GLOBE NEWSWIRE) — Gene Therapy Global Market to Observe Stupendous Growth at a CAGR of ~19% by 2028 | DelveInsight

The gene therapy market is expected to surge in the coming years owing to the rising prevalence of serious genetic disorders such as spinal muscular atrophy, hemophilia, retinitis pigmentosa, and others. In addition, the increasing number of pharmaceutical trials for gene therapy, growing advances in gene editing tools, and others are also contributing to the overall growth of the gene therapy market during the forecast period of 2023–2028. 

DelveInsight’s Gene Therapy Market Insights report provides the current and forecast market analysis, individual leading gene therapy companies’ market shares, challenges, gene therapy market drivers, barriers, trends, and key market gene therapy companies in the market.

Key Takeaways from the Gene Therapy Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global gene therapy market during the forecast period. 
• Notable gene therapy companies such as Novartis AG, F. Hoffmann-La Roche Ltd., Ferring B.V., bluebird bio, Inc., Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen, Prevail Therapeutics, CSL, and several others, are currently operating in the gene therapy market.
• In February 2023, CSL received the European Commission approval for Hemgenix, which is the first gene therapy to gain EU approval for hemophilia B.
• In December 2022, Ferring Pharmaceuticals announced that it had received the US Food and Drug Administration (FDA) approval for Adstiladrin® (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
• In August 2022, PTC Therapeutics, Inc. received marketing authorization for Upstaza (eladocagene exuparvovec), the first approved gene therapy treatment developed for aromatic L-amino acid decarboxylase (AADC) deficiency from European Commission.

To read more about the latest highlights related to the gene therapy market, get a snapshot of the key highlights entailed in the Global Gene Therapy Market Report

Gene Therapy Overview

A gene is a functional hereditary unit of life containing instructions for performing a certain function. Gene therapy is a cutting-edge treatment for cancer, chronic illness, infectious disease, and blood problems. Gene therapy entails replacing faulty genes in a patient’s body with good ones to treat or prevent disease progression. Somatic gene therapy and germline gene therapy are the two types of gene therapy based on the location of the target gene on a chromosome. It can potentially cure various disorders, including Parkinson’s, hemophilia, cystic fibrosis, Alzheimer’s, brain tumors, cancer, AIDS, SCID, and others. Biological vectors such as viruses, liposomes, and plasmids deliver the transgene to the host cell. These vectors are further divided into two types: viral vectors and non-viral vectors. Retroviruses, lentiviruses, adenoviruses, and adeno-associated vectors comprise the viral vector. Liposomes, transposons, and plasmids are examples of non-viral vectors. Physical methods for gene transfer include electroporation, sonication, gene gun, and photoporation.

Gene Therapy Market Insights

North America is expected to account for the highest proportion of the gene therapy market in 2023 out of all regions. The gene therapy market is expected to grow significantly in the region due to the importance of key growth factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and rapid regulatory approval for new products, among others.

Based on an assessment of these products’ gene therapy pipeline and clinical success rates, the US Food and Drug Administration stated in January 2019 that by 2025, the FDA would approve 10 to 20 gene therapy medicines annually. Furthermore, the FDA expects to receive 200 investigational new drug (IND) applications annually. As a result, an increase in the number of product development activities in the region will accelerate the expansion of the gene therapy market.

To know more about why North America is leading the market growth in the gene therapy market, get a snapshot of the Gene Therapy Market Outlook 

Gene Therapy Market Dynamics

The expanding number of people with genetic abnormalities and the growing therapeutic value of gene therapy in their treatment and management is the primary factor driving the expansion of the gene therapy industry. Moreover, the rapid expansion of the gene therapy pipeline is projected to drive the gene therapy market. For instance, Pfizer Inc. announced favorable top-line findings from the Phase III BENEGENE-2 study of fidanacogene elaparvovec, an experimental gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B in December 2022.

However, ethical concerns about gene therapy diagnostics and the high treatment costs may limit the overall growth of the gene therapy market.

Additionally, the gene therapy market was significantly impacted during the COVID-19 pandemic due to lockdown impositions as a measure to prevent the spread of COVID-19 infection, which resulted in the suspension of gene therapy research and development activities due to a lack of raw materials and required workforce. Nonetheless, the gene therapy market is recovering due to the introduction of COVID-19 vaccines and the resumption of activities in all sectors, including healthcare and pharmaceutical, providing ample opportunities for the gene therapy market to grow at significant revenue during the forecast period.

Get a sneak peek at the gene therapy market dynamics @ Gene Therapy Market Dynamics Analysis

Report Metrics	Details
Coverage	Global
Study Period	2020–2028
Base Year	2022
Gene Therapy Market CAGR	~19%
Key Gene Therapy Companies	Novartis AG, F. Hoffmann-La Roche Ltd., Ferring B.V., bluebird bio, Inc., Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen, Prevail Therapeutics, CSL, among others

Gene Therapy Market Assessment

• Gene Therapy Market Segmentation
  • Gene Therapy Market Segmentation By  Vector Type: Viral and Non-Viral
  • Gene Therapy Market Segmentation By  Delivery Type: Ex Vivo and In Vivo
  • Gene Therapy Market Segmentation By Indication: Neurological, Oncological, Hematological, Ophthalmological, and Others
  • Gene Therapy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the gene therapy market are set to emerge as the trendsetter explore @ Gene Therapy Companies 

Table of Contents 

1	Report Introduction
2	Executive summary
3	Regulatory and Patent Analysis
4	Key Factors Analysis
5	Porter’s Five Forces Analysis
6	COVID-19 Impact Analysis on Gene Therapy Market
7	Gene Therapy Market Layout
8	Global Company Share Analysis – Key 3-5 Companies
9	Gene Therapy Market Company and Product Profiles
10	Project Approach
11	About DelveInsight

Interested in knowing the gene therapy market by 2028? Click to get a snapshot of the Gene Therapy Market Trends

Related Reports

Gene Therapy Competitive Landscape

Gene Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy companies, including Novartis, Johnson & Johnson, Fibrocell Technologies, Pfizer, HELIXMITH Co., Ltd., Sarepta Therapeutics, REGENXBIO, Solid Biosciences Inc., Lexeo Therapeutics, Spark Therapeutics, Xalud Therapeutics, uniQure, Ultragenyx Pharmaceutical, Nanoscope Therapeutics, among others.

Gene Therapy In CNS Disorder Market

Gene Therapy In CNS Disorder Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gene therapy In CNS disorder companies, including UniQure Biopharma, Brain Neurotherapy Bio, NeuroGeneration, Eli Lilly and Company, Sio Gene Therapies, among others.

Adeno-Associated Virus Vectors in Gene Therapy Market

Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.

Adeno-Associated Virus Vectors in Gene Therapy Pipeline

Adeno-Associated Virus Vectors in Gene Therapy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.

Gene Therapy For Ocular Rare Disease Pipeline

Gene Therapy For Ocular Rare Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy for ocular rare disease companies, including Roche Holding, Novartis, Ocugen, among others.

Gene Therapies For Cardiomyopathies Pipeline

Gene Therapies For Cardiomyopathies Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapies for cardiomyopathies companies, including XyloCor Therapeutics, LEXEO Therapeutics, Stelios Therapeutics, Tenaya Therapeutics, Renova Therapeutics, among others.

Gene And Cell Therapies Targeting CNS Disorders Pipeline

Gene And Cell Therapies Targeting CNS Disorders Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene and cell therapies targeting CNS disorders companies, including UniQure Biopharma, Brain Neurotherapy Bio, NeuroGeneration, Eli Lilly and Company, Sio Gene Therapies, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs

Gene Therapy: The Next Milestone in Treating Complex Diseases

AAV Vectors in Gene Therapy

Gene Therapy for Duchenne Muscular Dystrophy

Avrobio’s Gene Therapy for Cystinosis Treatment

Gene Therapy for Hemophilia

Emerging Gene Therapy in the Dermatology

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.